Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
The use of clopidogrel as part of DAPT will be associated with lower bleeding rates compared to ticagrelor in patients with chronic thrombocytopenia requiring Percutaneous intervention (PCI )with Drug Eluting Stent (DES) or Bare Metal Stint(BMS).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• ≥ 18 years
• PCI with either DES or BMS during study time period (April 1, 2018 through July 1 2021)
• Thrombocytopenia defined as platelet count \<100 x103 /µL on at least one occasion prior to PCI
• At least one dose of DAPT post-PCI with aspirin and either clopidogrel or ticagrelor
Locations
United States
Texas
Methodist Dallas Medical Center
RECRUITING
Dallas
Contact Information
Primary
Bethany Brauer
mhsirb@mhd.com
214-947-4681
Backup
Colette Ngo Ndjom
mhsirb@mhd.com
214-947-1289
Time Frame
Start Date: 2022-08-22
Estimated Completion Date: 2024-08-22
Participants
Target number of participants: 300
Related Therapeutic Areas
Sponsors
Leads: Methodist Health System